Risk of Delays and Additional Expenditure in Overseas Business Expansion
First written in FY2017. 2 of 4 entries say "Restated". Latest entry: FY2021-Q3.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2021, 1 year before the typical company in this theme (2022).
The whole theme swung hardest in 2025: 8 of 13 companies on the "Worse" side.
3 other companies' latest entry also says "Materialised".
- FY2021-Q3MaterialisedAnnual report
「Subsequently, after considering the stagnation of economic activity in Europe caused by the COVID-19 pandemic and the financial position of Human Metabolome Technologies Europe B.V., among other factors, the company examined the optimal business structure for the European market going forward. As a result, it decided to centralize management through its US subsidiary, close its sales base in Europe, and dissolve and liquidate the company.」
Against the backdrop of stagnating economic activity in Europe and the financial condition of its subsidiary, the company actually decided to change the form of its overseas operations by closing its European base and dissolving the subsidiary. - FY2020RestatedAnnual report
「If business expansion in these regions is delayed for any reason, or if expenditures increase beyond the Group’s plans, this could affect the results of operations and future business expansion of our Group.」
The company continues to identify the risks of delays and cost overruns in expansion into North America, Europe and the Asia-Pacific region. - FY2019RestatedAnnual report
「We plan to accelerate overseas expansion by strengthening sales activities in North America and the Asia-Pacific region and making a full-scale entry into Europe. However, if business expansion in these regions is delayed for any reason, or if expenditures increase beyond the Group’s plans, this could affect the results of operations and future business expansion of our Group.」
The company continues its policy of overseas expansion into North America, the Asia-Pacific region and Europe, together with the risks of delays and cost overruns. - FY2017First statedAnnual report
「If business expansion in these regions is delayed for any reason, or if expenditures increase beyond the Group’s plans, this could affect the results of operations and future business expansion of our Group.」
Against its policy of accelerating expansion into North America, Asia-Pacific and Europe, the company identifies the risks of delays to its plans and cost overruns.